Depression vs Anxiety — Clinical Trial Comparison
Depression
Persistent low mood and loss of interest
Anxiety Disorders
Excessive worry and fear responses
Depression and anxiety are the two most common mental health conditions in the UK, and they frequently co-occur. While they share many treatments, their clinical trial landscapes have important differences in what's being tested, who's eligible, and what outcomes are measured.
Key Differences at a Glance
| Feature | Depression | Anxiety Disorders |
|---|---|---|
| Primary symptoms | Low mood, anhedonia, fatigue, hopelessness | Excessive worry, panic, avoidance, physical tension |
| Common subtypes | MDD, treatment-resistant, bipolar depression, postpartum, seasonal | GAD, social anxiety, panic disorder, PTSD, OCD, phobias |
| Severity scoring | PHQ-9, MADRS, HAM-D | GAD-7, HAM-A, CGI-S |
| Co-occurrence rate | ~50% also have anxiety | ~60% also have depression |
| NICE first-line treatment | CBT + SSRI/SNRI | CBT + SSRI/SNRI |
| Treatment-resistant % | ~30% of MDD patients | ~25% of GAD patients |
Clinical Trial Availability
| Trial Aspect | Depression | Anxiety Disorders |
|---|---|---|
| UK trials actively recruiting | 80–130 studies | 40–70 studies |
| Most common trial phase | Phase 2–3 | Phase 2–3 |
| Top interventions tested | Novel antidepressants, psychedelics, neuromodulation, digital therapeutics | SSRIs/SNRIs, CBT delivery formats, neuromodulation, exposure therapy tech |
| Psychedelic trials | Psilocybin (multiple UK sites) | MDMA (primarily PTSD) |
| Digital/app-based trials | Growing rapidly | Growing rapidly |
| Treatment-resistant focus | Major trial category | Emerging category |
Exciting Emerging Treatments
Depression Trials
- Psilocybin-assisted therapy — multiple UK trials, including treatment-resistant depression
- Ketamine/esketamine — rapid-acting for TRD, nasal spray and IV formulations
- Transcranial Magnetic Stimulation (TMS) — non-invasive brain stimulation
- Novel glutamate modulators — targeting NMDA receptors
- Orexin receptor antagonists — dual antidepressant + sleep benefit
- Digital therapeutics — app-delivered CBT and behavioural activation
Anxiety Trials
- MDMA-assisted therapy — primarily for PTSD, showing strong results
- Virtual reality exposure therapy — for phobias, social anxiety, PTSD
- D-cycloserine augmented CBT — enhancing exposure therapy outcomes
- Neurofeedback — real-time brain activity training
- Novel anxiolytics — non-benzodiazepine targeted agents
- App-based interventions — scalable digital mental health trials
💡 Treatment-resistant? You have the most trial options
If you've tried 2+ medications without adequate response, you may qualify for treatment-resistant depression or anxiety trials. These are often the most innovative studies, testing cutting-edge approaches like psychedelics, neuromodulation, and novel mechanisms. Treatment resistance is actually a gateway to the most exciting research.
Eligibility Differences
Depression Trial Criteria
- Minimum severity score required (PHQ-9 ≥ 10 or MADRS ≥ 20 typical)
- Treatment-resistant trials require documented failure of 2+ adequate antidepressant trials
- Bipolar depression must be distinguished from unipolar — many MDD trials exclude bipolar
- Active suicidal ideation may exclude from some trials (others specifically include it)
- Washout period from current medications typically required (2–4 weeks)
Anxiety Trial Criteria
- Specific anxiety disorder diagnosis required (GAD, social anxiety, PTSD, OCD, etc.)
- Severity thresholds vary by disorder (GAD-7 ≥ 10 for GAD trials)
- PTSD trials require specific trauma exposure and timeframe criteria
- OCD trials may require minimum Y-BOCS scores
- Comorbid depression is common and often allowed, but must be secondary in severity
💭 Depression Trials
Find actively recruiting depression clinical trials across the UK
View Depression TrialsNeed mental health support now?
If you're in crisis, contact the NHS at 111 or the Samaritans at 116 123 (free, 24/7). Clinical trials are not emergency services.